Effect of intravesical glycosaminoglycan substitution therapy on bladder pain syndrome/interstitial cystitis, bladder capacity and potassium sensitivity.
OBJECTIVE
To evaluate changes in bladder capacity and potassium sensitivity after glycosaminoglycan (GAG) substitution therapy.


METHODS
The study population comprised two groups of female patients with bladder pain syndrome/interstitial cystitis (BPS/IC): responders (those with symptom improvement) and non-responders (those without symptom improvement) after a 10-week period of intravesical, episodic, weekly, GAG substitution therapy. A total of 27 volunteers with increased pre-therapeutic potassium sensitivity were enrolled in the study and re-evaluated using the modified comparative potassium test (maximal bladder capacity with a saline solution versus a 0.2 M KCl solution) following intravesical GAG substitution therapy.


RESULTS
In the 13 responders, the average maximal bladder capacity increased by 17% with the saline solution and by 101.5% with the 0.2 M KCl solution. In the 14 non-responders, post-therapeutic average maximal bladder capacity was decreased by 35% with the saline solution and remained relatively unchanged after instillation with a 0.2 M KCl solution.


CONCLUSIONS
These data demonstrate that in patients who respond symptomatically to intravesical GAG substitution therapy, cystometric bladder capacity is increased, whereas non-responders experience a decrease in bladder capacity.
Daha
Lukas K
LK
Department of Urology, Municipal Hospital Hietzing, Vienna, Austria. lukas.daha@wienkav.at
Riedl
Claus R
CR
Lazar
Dara
D
Simak
Reiner
R
Pflüger
Heinz
H
D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D018856:Cystitis, Interstitial / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006025:Glycosaminoglycans / Q000008:administration & dosage* / Q000627:therapeutic use*; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D010426:Pentosan Sulfuric Polyester / Q000008:administration & dosage / Q000627:therapeutic use; D011189:Potassium Chloride / Q000494:pharmacology*; D011446:Prospective Studies; D001743:Urinary Bladder / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology
D006025:Glycosaminoglycans; D010426:Pentosan Sulfuric Polyester; D011189:Potassium Chloride; D006820:Hyaluronic Acid